2023 World Conference on Lung Cancer (Posters)-P2.22. NUT Midline Carcinoma (NC) Deciphering the Standard of Care in an Ultra-rare Cancer

P2.22. NUT Midline Carcinoma (NC) Deciphering the Standard of Care in an Ultra-rare Cancer - PDF(Slides)

Pdf Summary

Nut midline carcinoma (NC) is an extremely rare and underdiagnosed cancer with a poor prognosis. It is caused by the rearrangement of NUTM1, which leads to cell proliferation and dedifferentiation. Due to its low frequency and heterogeneity, there is limited evidence on how to treat NC effectively. This study aimed to evaluate the efficacy of different treatments in NC patients.<br /><br />The study included 24 patients, with a median age of 34 years. Most patients were men. The baseline characteristics of the patients varied, with the majority having head and neck or thoracic primary locations. The genetic alterations and prognostic groups also varied among patients. <br /><br />For patients treated with a curative intent, a multimodal approach was associated with better outcomes. The progression-free survival (PFS) for those treated with surgery alone was 1.1 months, while the combination of surgery with adjuvant treatment had a PFS of 6.7 months. The overall survival (OS) varied depending on the treatment approach.<br /><br />In the palliative setting, the optimal systemic treatment regimen remains uncertain. Different chemotherapy schemas were used, and their effectiveness varied. Further exploration of chemo-immunotherapy schemas is needed.<br /><br />Overall, the study highlights the need for international collaboration and the establishment of registries to gather more evidence on the best standard of care for NC. Additionally, the study suggests that new therapies targeting epigenetics could offer hope for improving the survival of patients with NC.

Asset Subtitle

Maria Virginia Sanchez-Becerra

Meta Tag

Speaker Maria Virginia Sanchez-Becerra

Topic Other Thoracic Malignancy

Keywords

Nut midline carcinoma

underdiagnosed cancer

NUTM1 rearrangement

cell proliferation

dedifferentiation

treatment efficacy

curative intent

progression-free survival

palliative setting

epigenetics